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1. Introduction 
Diabetic retinopathy (DR) is a significant cause of global blindness; a major cause of 
blindness in the world.There is emerging evidence that retinopathy is initiated and 
propagated by inflammation and angiogenesis. Increased cytokines and growth factors, in 
conjunction with redox stress, contribute to the development and progression of DR of 
abnormalities of endothelial cells and pericytes in DR. 
The four traditional metabolic pathways involved in the development of DR include: 
increased polyol pathway flux, advanced glycation end-product formation, activation of 
protein kinase Cisoforms and hexosamine pathway flux. These pathways individually 
and synergistically contribute to angiogenic growth factors, anti-angiogenic factors 
resulting in significant microvascular blood retinal barrier remodeling. The pathways are 
associated with inflammation and angiogenesis,either. Preventing or delaying the 
blindness associated with these intersecting abnormal metabolic pathways may be 
approached through strategies targeted to reduction of tissue inflammation. 
Understanding these abnormal metabolic pathways and the accompanying inflammation 
and angiogenesis mayprovide both the clinician and researcher a new concept of 
approaching this complicated disease process.  
2. Diabetic Retinopathy (DR) 
DR is associated with the following structural features: basement membrane (BM) 
thickening, pericyte loss,microaneurysms, intraretinal microvascular abnormalities(IRMA), 
diabetic macular edema (DME) and pre-retinal neovascularization,processes which can lead 
to blindness through hemorrhage and tractional retinal detachment1. Retinal endothelial 
cells (EC) are supported and sealed by a nearly equal number of pericytes in the retinal optic 
nerve fiber, inner and outer plexiform and choroidal layers creating a blood retinal barrier 
(BRB) of closed capillaries
1,2
. 
The vascular disruptions of DR/DME are characterized by abnormal vascular flow, 
disruptions in permeability,and/or closure or nonperfusion of capillaries. 
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A hallmark of early DR is the change in the structure and cellular composition of the 
microvasculature3. 
In early stages of DME, breakdown of the inner blood-retinal barrier may occur, resulting in 
accumulation of extracellular fluid in the macula4,5.Pericytes are essential cellular components 
in the regulation of retinal capillary perfusion, and damage to these cells in diabetes leads to 
altered retinal hemodynamics, including abnormal autoregulation of retinal blood flow6. Loss 
of retinal pericytes represents another early microaneurysm formation7-9. 
There is evidence that retinal leukostasis may also play an important role in the 
pathogenesis of DR. Leukocytes possess large cell volume, high cytoplasmic rigidity, a 
natural tendency to adhere to the vascular endothelium, and a capacity to generate toxic 
superoxide radicals and proteolytic enzymes10. In diabetes,there is increased retinal 
leukostasis, which affects retinal endothelial function, retinal perfusion, angiogenesis, and 
vascular permeability. And, leukocytes in diabetes are less deformable, a higher proportion 
are activated, and they may be involved in capillary nonperfusion, endothelial cell damage, 
and vascular leakage in the retinal microcirculation10. A study showed that diabetic vascular 
leakage and nonperfusion are temporally and spatially associated with retinal leukostasis in 
streptozotocin induced diabetic rats11. There are many capillary occlusions by leukocytes 
and capillary dropout or degeneration associated with leukocytes in the diabetic retina10. 
Serial acridine orange leukocyte fluorography and fluorescein angiography(FA) show 
trapped leukocytes directly associated with areas of downstream nonperfusion in the 
diabetic retinal microcirculation10.  
A number of proangiogenic, angiogenic and antiangiogenic factors are involved in the 
pathogenesis and progression of diabetic retinal disease, Vascular Endothelial Growth 
Factor (VEGF) being one of the most important. Other growth factors, which are known to 
participate in the pathogenesis of the disease, are: Platelet Derived Growth Factor (PDGF), 
Fibroblast Growth Factor (FGF), Hepatocyte Growth Factor (HGF), Transforming Growth 
Factor (TGF), Placental Endothelial Cell Growth Factor (PlGF), Connective Tissue Growth 
Factor (CTGF). Other molecules that are involved in the disease mechanisms are: intergrins, 
angiopoietins, protein kinase C (PKC), ephrins, interleukins, leptin, angiotensin, monocyte 
chemotactic protein (MCP), vascular cell adhesion molecule (VCAM), tissue plasminogen 
activator (TPA), and extracellular matrix metalloproteinases (ECM-MMPs). 
3. Vascular Endothelial Growth Factor (VEGF) 
The VEGFs are a family of proteins that are mitogenic for vascular endothelial cells and 
increase vascular permeability. VEGF is important in fetal vascular development,with VEGF 
levels diminishing after birth. VEGF is expressed by retinal glial cells12 and vascular 
endothelial cells13. VEGF is secreted by numerous ocular cell types14, and increased levels of 
VEGF have been detected in ocular fluids of patients with proliferative diabetic 
retinopathy15. In vivo, administration of neutralizing VEGF antibodies to experimental 
animals reverses high-glucose–induced vascular hyperpermeability16, which is an early 
manifestation of endothelial dysfunction in diabetic patients17. 
VEGF expression is regulated largely by hypoxia, but it also accumulates in the retina early 
in diabetes, before any retinal hypoxia is yet apparent 18-20. It is produced by multiple cell 
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types in the retina in diabetes, including ganglion cells, Mueller cells, and pericytes. 
Repeated injections of high concentrations of VEGF in the eyes of nondiabetic monkeys 
result in retinal changes which in some ways resemble those in the early stages of diabetic 
retinopathy, including vascular tortuosity and microaneurysm21, 22. Genetic factors are 
important in the pathogenesis of DR; there is a clear association of increased expression of 
VEGF with DR as well as numerous VEGF polymorphisms that are linked to increased 
VEGF levels and DR.23 Their result has demonstrated that the development of different 
stages of diabetic retinopathy is closely correlated with an increased VEGF level in the 
retina24.Clinical trials using anti-VEGF therapies are showing promising results against 
stages of diabetic retinopathy25. 
VEGF is a potent vascular permeability factor, and VEGF upregulation has been linked to 
neovascular eye diseases including diabetic retinopathy23. VEGF-induced neovascular 
changes have previously been demonstrated on animal models based on increasing VEGF 
levels through implants26, recombinant adenovirus-mediated VEGF expression27, 28, or 
transgenic technologies29, 30. 
In the eye, one of the earliest signs of diabetic retinopathy is retinal capillary occlusion, 
blocking blood flow and generating capillary-free areas31. Hypoxic conditions could develop 
in these capillary-free areas, and this in turn could induce the upregulation of angiogenic 
factor production, such as VEGF and intercellular adhesion molecules32, 33. The increased 
concentration of angiogenic factors would then cause vascular changes including vascular 
dilatations, tortuous blood vessels, microaneurysms, and endothelial cell proliferation. 
Subsequently,over an extended period of time, these changes could result in the 
development of poorly matured leaky vessels34, 35.Previous histological studies have 
demonstrated a strong correlation between endothelial cell proliferation, pericyte loss, and 
the development of microaneurysm36. Incidentally, VEGF, which is a known factor of 
endothelial cell proliferation, has also been shown to promote pericyte detachment and 
loss37.  
Troglitazone and rosiglitazone, another thiazolidinediones (TZD), increase VEGF mRNA 
levels in 3T3-L1 adipocytes.Although increased VEGF may be beneficial for subjects with 
macroangiopathy and troglitazone is currently not available for clinical use, vascular 
complications, especially diabetic retinopathy, must be followed with great caution in 
subjects treated with TZD 38.  
Federico et al39 tested selective PPARǂ and PPARǄ synthetic agonists potential ability to 
stimulate neoangiogenesis in well-established in vitro and in vivo assays. They found that 
specific and selective activation of PPARǂ and PPARǄ leads to increased production of 
VEGF, a prototypical angiogenic agent, and formation of endothelial tubules when 
endothelial cells are co-cultured with interstitial cells. In vivo, PPARǂ and PPARǄ synthetic 
agonists stimulate angiogenesis in the mouse corneal neovascularization assay, whereas 
fibrates and TZDs are unable to induce angiogenesis in the same experimental setting. 
PPARǂ- and PPARǄ-angiogenic process is associated with increased expression of VEGF 
and increased phosphorylation of endothelial nitric oxide (NO) synthase(eNOS) and Akt. 
Finally, it may be inhibited by blocking VEGF activity. The ability of PPARa and PPARǄ 
agonists to induce neoangiogenesis might have important implications for the clinical and 
therapeutic management of type 2 diabetes39.  
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4. Pigmented Epithelial Derived Factor (PEDF) 
PEDF is a member of the serine protease inhibitor (serpin) superfamily with neurotrophic 
and antiangiogenic properties, and a decreased level of PEDF in the eye is important in the 
pathogenesis of proliferative DR
40
. In the retina, angiogenesis is regulated by two 
counterbalancing systems: angiogenic stimulators, such as VEGF, and angiogenic inhibitors, 
such as angiostatin and pigment epithelium–derived factor (PEDF)
40
.  
PEDF is a natural extracellular component of the retina and has been found in the vitreous 
and aqueous humors. Decreased levels of PEDF were reported in the ocular fluids of 
patients with angiogenic eye diseases41. PEDF has potent antiangiogenic activity in retinal 
EC growth and migration and suppressed ischemia-induced retinal neovascularization
42
. 
Pericyte loss is one of the earliest hallmarks of DR and an important reason for pericyte loss 
is reactive oxygen species (ROS)
43
. In DR, PEDF has a novel benefit since PEDF protects 
retinal pericytes against oxidative stress-induced injury through its anti-oxidative 
properties, which might slow the development of diabetic retinopathy43.PEDF protects 
against high glucose or ROS induced pericyte apoptosis and dysfunction through its anti-
oxidative properties via induction of glutathione
44
. 
Guoquan et al45 compared susceptibilities of Sprague Dawley(SD) and Brown Norway(BN) 
rats with ischemia-induced retinal neovascularization. They found that the hyperoxia-
treated BN rats showed a significant reduction in retinal PEDF and a substantial increase of 
VEGF at both the protein and RNA levels, resulting in an increased VEGF-to-PEDF ratio. 
The results suggested that BN rats developed more severe retinal neovascularization, which 
correlated with a greater increase of the VEGF-to-PEDF ratio in BN than in SD rats45.  
PEDF, a potent inhibitor of angiogenesis, has been found to be involved in the pathogenesis 
of PDR46, 47. It is well known that there are quite a few stimulators and inhibitors of 
angiogenesis in the eye; among them, VEGF has been identified as a primary angiogenic 
stimulator48 and PEDF as a major angiogenic inhibitor47. The time course of the VEGF-to-
PEDF ratio change correlated with the development and progression of retinal 
neovascularization. The VEGF-to-PEDF ratio represented a dynamic balance between 
angiogenic stimulators and inhibitors; and disturbance of the balance played a key role in 
the pathogenesis of DR45, 49, 50. In vitro study revealed that lowering of the VEGF-to-PEDF 
mRNA ratio could inhibit the migration of uveal melanoma cells51. 
Additionally, PEDF induces the ERK signal cascade which contributes to retinal pigment 
epithelial cell cytoprotection against oxidative stress
52
. Thus, retinal cells including the BRB 
capillaries and their supportive and protective pericytes may possess a system capable of 
efficiently responding to PEDF
43, 44
. 
Retinal ischemia induces intraocular neovascularization,presumably by stimulating the 
expression of angiogenic growth factors and by inhibiting the release of antiangiogenic 
cytokines53, 54. Vitreal levels of angiogenic growth factors have been shown to be directly 
associated with the degree of retinal angiogenesis15, 55. PEDF protects cerebellar granule cells 
against neurotoxic agents56 and is also called early population doubling level cDNA-1 (EPC-
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1), reflecting its upregulation during cell cycle arrest (G0) in young but not in senescent 
cultured fibroblasts57. 
PEDF has been shown to be a highly effective inhibitor of angiogenesis in animal and cell 
culture models. The production of PEDF was decreased by hypoxia47, which is also a central 
pathogenic stimulus in PDR. Immunoneutralization of PEDF diminished the ability of 
cadaveric human vitreous to inhibit migration of endothelial cells, thereby demonstrating 
that a loss of PEDF is functionally important in mediating angiogenic properties of human 
vitreous ex vivo. Most importantly, systemically administered PEDF prevented aberrant 
blood vessel growth in a murine model of ischemia-induced retinopathy58.  
PEDF has been shown to be a major antiangiogenic growth factor in the mammalian eye. 
Joachim41 et al analyzed the in vivo regulation of PEDF in patients with and without hypoxic 
eye disease. Their data strongly support the concept that retinal angiogenesis is induced by 
loss of the major angiogenesis inhibitor in the eye, PEDF, in combination with an increased 
expression of angiogenic growth factors such as VEGF. These findings suggest that 
substitution of angiogenesis inhibitors may be an effective approach in the treatment of PDR41.  
In the study of Zhi59 et al ,diabetic rats and control animals were randomly assigned to 
receive perindopril or vehicle for 24 weeks, and bovine retinal capillary endothelial cells 
(BRECs) were incubated with normal or high glucose with or without perindopril. The 
results showed the VEGF-to-PEDF ratio was increased in the retina of diabetic rats; 
perindopril lowered the increased VEGF-to-PEDF ratio in diabetic rats and ameliorated the 
retinal damage. In BRECs, perindopril lowered the hyperglycemia-induced elevation of 
VEGF-to-PEDF ratio by reducing mitochondrial ROS and the decreased ROS production 
was a result of perindopril induced upregulation of PPARY and UCP-2 expression59.  
Although VEGF is the major factor in the initiation of advanced stages of diabetic 
retinopathy, it is increasingly recognized that PlGF is a significant factor in promoting the 
aberrant angiogenesis characteristic of a variety of pathological states.  
5. Adiponectin (ADPN) 
The adipocyte derived factor ADPN is an insulin sensitivity activator, and is correlated to 
retinal redox stress and remodeling in metabolic syndrome and T2DM. Low levels of serum 
ADPN levels were found to be correlated with the severity of retinopathy
60
. Insulin-
sensitizing agents reduce pathological retinal microvessel formation through ADPN 
mediated modulation of tumor necrosis factor alpha (TNFα) production61. ADPN’s effect 
on diabetic retinopathy is not clear. However, ADPN induces eNO production by 
stimulating phosphorylation and activation of eNOS. ADPN inhibits specific binding of 
oxidized LDL and its uptake by macrophages. ADPN possesses anti-inflammatory 
properties and thus may negatively modulate the process of atherogenesis
62, 63
. 
In the early phase of diabetic retinopathy, hyperglycemia initiates endothelial cell injury, 
retinal vessel loss, and ischemia,as well as changes in leukocyte adhesion to the vascular 
endothelium64, 65. These conditions subsequently lead to the overproduction of various 
proangiogenic factors and proinflammatory cytokines, which, in turn, promotes abnormal 
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neovascular changes66.The primary goal for treatment of ischemic retinopathy is to preserve 
vision through the inhibition of abnormal neovascularization and vascular damage. 
Adiponectin is a circulating adipose-derived cytokine with antiinflammatory properties67, 
68.In animal models,adiponectin deficiency is associated with the increased inflammatory 
responses under conditions of stresses including overnutrition and ischemic insult69, 70. In 
addition, adiponectin has been shown to protect against the development of various 
diseases including detrimental cardiac and vascular remodeling,ischemic stroke and 
increased albuminuria69, 71-74. In human populations, circulating adiponectin levels inversely 
correlate with the inflammatory marker C-reactive protein levels in blood stream67, 75, 76. Low 
plasma adiponectin levels are associated with the increased prevalence of type 2 diabetes 
and its macrovascular complications including ischemic heart disease63, 67, 77. 
Clinical studies regarding the relationship between plasma adiponectin level and 
retinopathy in diabetes have been inconclusive78, 79. Higuchi et al investigated whether 
adiponectin affects the retinal vascularization and inflammation in a mouse model of 
ischemia-induced retinopathy.When neonatal mice were subjected to ischemia-induced 
retinopathy, pathological retinal neovascularization during ischemia was exacerbated in 
adiponectin-knockout (APN-KO) mice compared with wild-type mice. APN-KO mice also 
exhibited increased leukocyte adhesion and tumor necrosis factor (TNF)-a expression in 
hypoxic retina. Adenovirus-mediated overexpression of adiponectin attenuated hypoxia-
induced pathological retinal neovascularization by 35% in wild-type mice and by 40% in 
APN-KO mice and leukostasis by 64% in wild-type mice and by 75% in APN-KO mice, 
which were associated with reduced TNF-a production. TNF-a blockade diminished the 
enhanced pathological neovascularization in APN-KO mice, and the inhibitory effects of 
adiponectin overexpression on retinal neovascularization and leukocyte adhesion were 
abolished in mice lacking TNF-a. These data provide evidence that adiponectin protects 
against retinal vessel injury following pathological stimuli through modulation of TNF-a 
inflammatory responses80. 
ADPN suppresses adverse effects of inflammatory cytokines and reduces oxidative stress 
induced by oxidized LDL or high glucose in EC
62, 63
. ADPN inhibits VEGF-stimulated 
human coronary artery EC migration via cAMP/PKA dependent signaling including VEGF-
induced generation of ROS, which implicates it as an important role in vascular processes 
associated with diabetes. Because ADPN is known to act as an antioxidant, anti-
inflammatory, antiapoptotic and antifibrotic protein then its low levels may predispose it to 
a loss of any or all of the above known protective features of ADPN and directly or 
indirectly affect the capillary BRB including the pericyte. Importantly, ADPN may be used 
in the future as an early candidate biomarker of DR in CMS and T2DM. 
6. Leptin  
Not all patients with poor control of diabetes over long periods of time, develop 
retinopathy, suggesting the involvement of other mechanisms. The adipose tissue is an 
important endocrine organ that secretes many biologically active substances such as free 
fatty acids, adiponectin, and interleukin (IL)-6. They are collectively termed 
adipocytokines81. Leptin is one of adipocytokines, acting directly on the hypothalamus, 
thereby regulating food intake and energy expenditure82. The leptin receptor (Ob-R) is a 
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single transmembrane protein that belongs to the gp130 family of cytokine receptor 
superfamily. The leptin receptor has several alternatively spliced isoforms, one of which, a 
biologically active Ob-Rb isoform, is expressed not only in the hypothalamus but also in a 
variety of peripheral tissues, suggesting the direct action of leptin in the periphery. The 
peripheral actions of leptin include the activation of platelet aggregation , the modulation of 
immune function83, and the stimulation of vascular endothelial cell proliferation and 
angiogenesis84, 85. Upon binding to Ob-Rb, leptin has been shown to activate signal 
transducers and activators of transcription (STAT). 
A study has revealed that plasma leptin concentrations are elevated significantly in patients 
with proliferative diabetic retinopathy relative to those with nonproliferative retinopathy86. 
Furthermore, vitreous leptin concentrations are higher in patients with proliferative diabetic 
retinopathy or retinal detachment87. 
Using the retinopathy of prematurity model, a mouse model of ischemia-induced retinal 
neovascularization, Eri Suganami 88et al have demonstrated more pronounced retinal 
neovascularization in 17-day-old transgenic mice overexpressing leptin than in age-matched 
wild-type littermates. Leptin receptor expression was also detected in primary cultures of 
porcine retinal endothelial cells, where it upregulated VEGF mRNA expression. This effect 
was thought to be mediated at least partly through the activation of signal transducers and 
activators of transcription(STAT)3, because adenoviral transfection of the dominant negative 
form of STAT3 abolished the leptin-induced upregulation of VEGF mRNA expression in 
retinal endothelial cells. This study provides evidence that leptin stimulates the ischemia-
induced retinal neovasucularization possibly through the upregulation of endothelial VEGF88.  
7. Insulin-like Growth Factor-1 (IGF-1) 
Similar to VEGF, the activation of IGF-1 also increases PKC activation, so IGF-1 may be 
regulated by oxidative stress via the PKC pathway89. Retinal IGF-1 mRNA levels are lower 
in the human and diabetic rat when compared to age matched non-diabetic controls90 and 
IGF-1 can have direct mitogenic effects on retinal EC60.IGF-1 can stimulate glucose transport 
into retinal microvascular EC via activation of PKC and can modulate the expression and 
activity of VEGF
91
. 
Growth hormone and IGF-I have been suspected of playing a role in the progression of 
diabetic retinopathy. In a previous era, hypophysectomy was shown to lead to regression of 
proliferative retinopathy in a study of 100 patients92. Similarly, diabetic dwarfs with low 
systemic IGF-I levels due to growth hormone deficiency have a reduced incidence of 
proliferative DR compared with age- and sex matched diabetic patients. Such observations 
have raised interest in the use of growth hormone–inhibitory and antiproliferative 
somatostatin analogs to treat severe proliferative DR, however, a growth hormone receptor 
antagonist, pegvisomant, failed to induce regression of neovascularization 93. This negative 
result may have occurred because the treatment was initiated too late; treatment may need 
to have started prior to the development of proliferative DR. In another small-scale trial (23 
patients), octreotide (a somatostatin analog) treatment reduced the requirement for laser 
photocoagulation compared with conventional treatment in patients with either severe 
NPDR or early proliferative DR 94. Over the 15-month study, only1 of 22 octreotide-treated 
patients required photocoagulation compared with 9 of 24 conventionally treated patients. 
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8. Interleukin-1 Beta (IL-1β) 
Levels of the proinflammatory cytokine, IL-1ǃ , are known to be increased in retinas from 
diabetic rats95-97. Intravitreal injection of IL-1ǃ or exposure of retinal endothelial cells to the 
cytokine in vitro was shown to be capable of causing degeneration of retinal capillary 
endothelial cells98, but the relevance of these findings to capillary degeneration in vivo is not 
clear because the levels of IL-1ǃ likely were pharmacologically high. The role of IL-1ǃ in the 
pathogenesis of diabetic retinopathy recently has been more directly studied using diabetic 
mice in whom the enzyme responsible for IL-1ǃ production was inhibited or in whom the 
IL-1ǃ receptor was deleted. IL-1ǃ is the predominant product of caspase-1, and the 
biological activity of IL-1ǃ is mediated by binding to the cell surface receptor, IL-1R1. 
Activity of caspase-1 is increased in retinas of diabetic mice, galactosefed mice, and diabetic 
humans, and in retinal Müller cells incubated in elevated glucose concentration99. Inhibition 
of caspase-1 using minocycline inhibited the diabetes induced increase in IL-1ǃ and 
decreased degeneration of retinal capillaries in those animals95. Likewise, inhibition of IL-1ǃ 
signaling using IL-1ǃ receptor knock-out mice protected the animals from diabetes-induced 
retinal pathology at 7 months duration of diabetes95. The results indicate that activation of 
caspase-1 and subsequent production of IL-1ǃ play an important role in the development of 
diabetes induced retinal pathology. One known action of IL-1ǃ is to activate NF-κ B. 
IL-1ǃ gene expression is known to reside in EC and glial cells and its expression is 
significantly upregulated in high glucose conditions allowing for BRB allowing 
inflammatory cells to increase their migration across the BRB
98
.  
IL-1ǃ is known to increase the expression of VEGF in retinal EC, and induces the expression 
of various genes whose promoters are regulated through complex interactions with 
NFκB100. IL-1ǃ has been found to be increased in streptozotocin diabetic rat models98 and IL-
1ǃ accelerates apoptosis in retinal capillary cells, specifically pericytes,through activation of 
NFκB, which is exacerbated by high glucose conditions101. NFκǃ is a key regulator of 
antioxidant enzymes and can initiate transcription of genes involved in apoptosis and 
additionally increases downstream inflammatory cytokines
101
. Importantly, IL-1ǃ 
activation—stimulation results in the translocation of NFκB from its cytosolic compartment 
to the nucleus where it initiates apoptotic genes and downstream inflammatory cytokines
101
. 
Additionally, IL-1ǃ is considered as one of the most potent stimuli for inducible NOS 
(iNOS), contributing to ongoing inflammation via induction of iNOS protein and 
augmentation of its activity
98
. IL-1ǃ receptor antagonism (IL-1 ǃra) in the retina and IL-
1ǃhave been shown to interfere with the development of not only diabetic retinopathy but 
also pancreatic islet inflammation and beta cell apoptosis in humans with T2DM
102
. 
9. Interleukin-6 (IL-6) 
The IL-6 cytokine shares common characteristics with VEGF, in that both are induced by 
hypoxia and hyperglycemia, and both play a role in vascular inflammation, permeability 
and angiogenesis
103
. Human studies have demonstrated that both VEGF and IL-6 were 
elevated in aqueous humor of patients with DR and even higher in those with proliferative 
DR indicating that VEGF and IL-6 play important roles in the development of DR
104
. Even 
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peripheral blood levels of IL-6 and TNFα were elevated in humans with DR with the 
highest elevations found in those with proliferative DR
105
. It has been shown that the AngII-
induced vascular alterations involved activation of NAD(P)H oxidase, IL-6, and increases in 
VEGF expression and further,that deletion of IL-6 prevented these effects of vascular 
inflammation in DR
106
. 
10. Monocyte Chemoattractant Protein (MCP-1) 
MCP-1 contributes to the recruitment of inflammatory cells (monocytes/monocyte derived 
macrophage/microglia) in injured tissue and ROS injury may play a role in DR and retinal 
detachment
107
. MCP-1 is a potential angiogenic factor in the proliferative phase of DR and is 
associated with proliferation DR
107
.Hyperglycemia increases the expression of MCP-1 in 
vascular EC
63
 and AGE-induced ROS generation induced the MCP-1 gene and mRNA 
expression
63
. Recently, aqueous samples in humans with DR have revealed higher levels of 
MCP-1 and VEGF when compared to nondiabetic subjects and authors further state that 
inflammatory changes may precede the development of neovascularization in proliferative 
DR
108
. 
11. Vascular Cell Adhesion Molecule (VCAM)  
Many specific growth factors mediate angiogenic process of diabetic retinopathy. VCAM-1, 
a member of the immunoglobulin supergene family of cellular adhesion molecules, is 
involved in the recruitment of leukocytes, their adhesion to vascular endothelium, and their 
subsequent migration into surrounding tissue. Interestingly, the expression of VCAM-1 has 
been found in epiretinal membranes from diabetic patients with PDR109, 110. In addition, it 
has been demonstrated that VCAM-1 promotes angiogenesis both in vitro and in vivo111, 
112.Olson et al. detected increased serum levels of VCAM-1 in diabetic patients with PDR113. 
Moreover, circulating levels of various adhesion molecules increase in patients with 
progressively worsening retinopathy, presumably as a result of shedding from both 
activated leukocytes and injured epithelium. However, systemic levels of VCAM-1 do not 
reflect the local production of VCAM-1 by the retina. Vitrectomy fluid samples obtained 
from diabetic patients with PDR are currently being used to explore indirectly 
the retinal synthesis of several proteins, including growth factors, cytokines, and adhesion 
molecules. Two previous studies demonstrated that soluble VCAM-1 is increased in the 
vitreous cavity of diabetic patients with PDR compared with the vitreous of patients 
undergoing macular hole repair114or from cadaveric eyes15.  
12. Connective Tissue Growth Factor (CTGF) 
The tissue repair process is regulated by a number of polypeptides including cytokines and 
growth factors. CTGF is a 38-kDa cysteinerich polypeptide that was originally identified 
from conditioned medium of human umbilical vein endothelial cells (HUVECs)115. CTGF, 
considered to be a downstream mediator of transforming growth factor-ß(TGF- ß)116, 117, is 
indicated to induce the production of extracellular matrix,such as collagen and fibronectin, 
and to cause fibrosis118. One study have shown that CTGF is overexpressed in the 
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membranes of eyes with PDR119, suggesting that CTGF might be involved in the 
pathogenesis of PVR and PDR. In addition, A study revealed that CTGF is overexpressed 
also in the vitreous with PVR and PDR and additionally demonstrated that various types of 
vitreoretinal cells could be the sources of CTGF120.  
Furthermore, CTGF has been recently indicated to be one of the regulators of angiogenesis. 
In vitro, CTGF has been demonstrated to have proangiogenic effects on Human umbilical 
vein endothelial cell121 and bovine aortic endothelial cells (BAECs)122, and in vivo, CTGF has 
been indicated to induce angiogenesis in rat corneal pocket implants123 and to be involved in 
tumor angiogenesis124 and choroidal neovascularization125, 126 
In the study of Takeshi et al, they demonstrated CTGF also stimulated the synthesis of 
fibronectin by hyalocytes and BRPEs without significant effect on collagen gel contraction 
by these cells. And CTGF promoted VEGF gene expression by hyalocytes and BRPEs. There 
was no significant correlation between the concentrations of CTGF and VEGF. These 
findings indicate that CTGF appears to be involved in the formation of proliferative 
membranes without direct regulation of their cicatricial contraction in the pathogenesis of 
proliferative vitreoretinal diseases. It is possible that CTGF has indirect effects by 
modulating the expression of VEGF127. 
13. Retinal Intercellular Adhesion Molecule-1 (ICAM-1) and CD18 
The retinal vasculature of diabetic humans contains increased numbers of leukocytes, a 
finding that coincides with the increased expression of ICAM-1 in retinal vasculature128. The 
phenomenon is also present in diabetic animal models and occurs whether the diabetes is 
spontaneous in nature or is induced11, 129, 130. The increased density of leukocytes in the 
retinal vasculature begins as early as 1 week following the onset of experimental diabetes 
and results in injury to the endothelium via a FasL-mediated mechanism; a process that 
leads to breakdown of the BRB 131, 132. Retinal ischemia is a second sight-threatening diabetic 
complication. Histolopathological analyses have shown that areas of angiographic non-
perfusion in vivo frequently co-localize to regions full of acellular capillaries, that is, 
basement membrane tubes devoid any viable endothelial cells or pericytes133.  
The leukocytes that adhere to the diabetic retinal vasculature use specific adhesion molecules 
such as the integrin ligand CD18, which forms the invariable portion of the heterodimers Mac-
1(CD11a/CD18) and LFA-1 (CD11b/CD18)134. Leukocytes use CD18 to tether themselves to 
intercellular adhesion molecule-1 (ICAM-1) on the surface of diabetic retinal vasculature. 
A work has established the role of CD18/ICAM-1 leukocyte adhesion in the pathogenesis of 
early diabetes-induced leukostasis and blood-retinal barrier breakdown131. The study of 
Antonia et al also showed that retinal leukostasis increased within days of developing 
diabetes and correlated with the increased expression of retinal intercellular adhesion 
molecule-1 (ICAM-1) and CD18135. Mice deficient in the genes encoding for the leukocyte 
adhesion molecules CD18 and ICAM-1 were studied in two models of diabetic retinopathy 
with respect to the long-term development of retinal vascular lesions. CD18−/− and ICAM-
1−/− mice demonstrated significantly fewer adherent leukocytes in the 
retinal vasculature at 11 and 15 months after induction of diabetes with STZ. And this 
condition is associated with fewer damaged endothelial cells and lesser vascular leakage. 
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Galactosemia of up to 24 months causes pericyte and endothelial cell loss and formation of 
acellular capillaries. However, these changes are significantly reduced in CD18- and ICAM-
1-deficient mice. Basement membrane thickening of the retinal vessels is increased in long-
term galactosemic animals independent of the genetic strain. Thus,the chronic, low-grade 
subclinical inflammation is responsible for many of the signature vascular lesions of diabetic 
retinopathy.These data highlight the central and causal role of adherent leukocytes in the 
pathogenesis of diabetic retinopathy135.  
Attraction and adhesion of leukocytes to the vascular wall are important components of 
inflammatory processes. This leukostasis has been found to be significantly increased in 
retinas of diabetic animals, and might contribute to the capillary nonperfusion in diabetic 
retinopathy. Leukocyte stiffness has been reported to be increased in diabetes (decreased 
filterability) and to contribute to the development of capillary nonperfusion in retinal 
vessels 136, 137. Diabetes increases expression of ICAM-1 in retinas of animals 11and 
interaction of this adhesion molecule on retinal endothelia with the CD18 adhesion molecule 
on monocytes and neutrophils contributes to the diabetes-induced increase in leukostasis 
within retinal vessels11. Leukostasis has been postulated to be a factor in death of retinal 
endothelial cells in diabetes131.  
White blood cells bind to ICAM-1 on the surface of endothelial cells as a component of a 
multistep process leading to adherence of the white blood cell to the endothelial wall11.This 
leukostasis is known to be increased in retinal blood vessels in diabetes, and this process is 
mediated via ICAM-111. ICAM-1 is upregulated by several stimuli, including VEGF, PARP 
activation, oxidative stress, and dylipidemia138-141, at least in part by NF-κ B.Genetically 
modified C57B1/6J mice have been used to explore the roles of ICAM-1 and its ligand on 
white blood cells (CD18) in the pathogenesis of diabetes-induced retinal vascular disease135.  
14. NF-κB 
NF-κ B is a widely expressed inducible transcription factor that is an important regulator of 
many genes involved in mammalian inflammatory and immune responses, proliferation 
and apoptosis. NF-κ B is composed of homodimers and heterodimers, the most abundant 
and best-studied form in mammalian cells consisting of the p65 and p50 subunits. Diabetes 
has been found to cause migration of the p65 subunit into the nucleus of retinal pericytes101, 
and of the p50 subunit into nuclei of retinal endothelial cells, pericytes, ganglion cells, and 
cells of the inner nuclear layer142. 
Evidence in support of an important role of NF-κ B in the pathogenesis of early stages of 
diabetic retinopathy is twofold. First, inhibition of proteins whose expression is regulated by 
NF-κ B (such as iNOS and ICAM) inhibit diabetes induced degeneration of retinal capillaries 
(described below).Second, compounds known to inhibit NF-κ B likewise inhibit the 
development of the retinopathy. For example, several different antioxidants which inhibit the 
development of capillary degeneration and pericyte loss in retinas of diabetic rats143 also 
inhibit the diabetes-induced activation of retinal NF-κ B138.Likewise, low-intermediate doses of 
salicylates (aspirin, sodium salicylate, and sulfasalazine) which inhibited NF-κ B activation in 
retinas of diabetic rats, also inhibited expression of inflammatory mediators like iNOS and 
ICAM-1, and capillary degeneration and pericyte loss in those animals143, 144. Aspirin is known 
to inhibit also production of prostaglandins, but salicylate and sulfasalazine have much less of 
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this activity, suggesting that the common action of these salicylates to inhibit retinopathy in 
diabetes was not primarily mediated by inhibition of prostaglandins.  
15. iNOS 
Inducible isoform of nitric oxide synthase(iNOS) expression is regulated at least in part by 
NF-κ B. Interestingly, experimental sympathectomy itself increases gene and protein 
expression of iNOS in retinas of nondiabetic rats145, suggesting that loss of sympathetic 
activity, such as which occurs in diabetes, might contribute to the upregulation of this 
inflammatory protein in the retina. 
In retinas of diabetic animals, increased levels of nitric oxide products (nitrotyrosine, nitrite, 
nitrate) have been reported144-146. Upregulation of iNOS has been found in retinas of 
experimental diabetic rodents and patients in most studies145-152. Diabetes-induced 
alterations in expression of other isoforms of nitric oxide synthase also have been 
reported153, 154. A possible role of iNOS in the pathogenesis of diabetic retinopathy is 
suggested by the studies of aminoguanidine. Aminoguanidine is a relatively selective 
inhibitor of iNOS155-158, and has been found to inhibit the diabetes-induced increase nitric 
oxide production and iNOS expression in retina145. 
Aminoguanidine also has been found to inhibit the development of the microvascular 
lesions of diabetic retinopathy in diabetic dogs159and rats160.The role of iNOS in the 
development of the early stages of diabetic retinopathy recently has been investigated 
directly using mice genetically deficient in iNOS161. In that study, wildtype diabetic mice 
developed the expected degeneration of retinal capillaries, as well as increase in leukostasis 
and superoxide generation. In contrast, diabetic mice deficient in iNOS did not develop 
these structural or functional abnormalities.  
16. Fas 
Fas levels are increased in retinas of diabetic rats132, 162. Blocking FasL in vivo has been 
shown to prevent endothelial cell damage, vascular leakage, and platelet accumulation in 
diabetes, suggesting that the Fas/FasL system might contribute to the diabetes-induced 
damage that contributes to the development of the retinopathy132, but its role in the 
development of retinal histopathology has not been assessed. 
17. Angiopoietin-1 
Angiopoietin-1 has been found to have anti-inflammatory actions, including inhibition of 
vascular permeability and adhesion protein expression163. When administered intravitreally 
to diabetic rats, angiopoietin-1 normalized blood-retinal barrier function, leukostasis and 
endothelial injury, and inhibited upregulation of retinal VEGF and ICAM-1mRNA and 
protein164. 
18. Hepatocyte Growth Factor (HGF) 
HGF in the etiopathogenesis of PDR remains to be elucidated. A lot of studies165-169 have 
found high intravitreous concentrations of HGF in patients with PDR. In the present study, 
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we consider all these confounding factors in order to evaluate the vitreous levels of HGF in 
patients with PDR and to investigate its relationship with VEGF and retinopathy activity. A 
total of 28 diabetic patients with PDR, in whom a vitrectomy was performed, were included 
in the study. Thirty nondiabetic patients with other conditions requiring vitrectomy but in 
whom the retina was not directly affected by neovascularization served as a control group. 
Patients in whom intravitreous hemoglobin was detectable by spectophotometry were 
excluded. HGF and VEGF were determined by enzyme-linked immunosorbent assay. 
Vitreal levels of both VEGF and HGF were higher in diabetic patients with PDR than in the 
control group. These differences remained highly significant after adjusting for serum 
levels. To explore the influence of the breakdown of the blood-retinal barrier and, in 
consequence, the increased serum diffusion that occurs in PDR patients, the levels of both 
HGF and VEGF were normalized for total vitreal protein concentration. After correcting for 
total vitreous protein concentration, the ratio of VEGF to vitreal proteins remained 
significantly higher in diabetic patients with PDR than in the control group, respectively. 
However, the ratio of HGF to vitreal proteins was lower in diabetic patients than in 
nondiabetic control subjects. The lower intravitreous levels of HGF obtained after correcting 
for intravitreal proteins in patients with PDR in comparison with nondiabetic control 
subjects suggest that serum diffusion largely explains the differences detected in the 
intravitreous HGF levels between these groups. The vitreous concentrations of VEGF were 
higher in patients with active PDR than in patients with quiescent PDR. By contrast, 
vitreous HGF was not related to PDR activity170.  
19. Angiotensin II 
Angiogenesis, the growth of new vessels, is a physiologic process that occurs under normal 
conditions. During these processes, angiogenesis is well regulated by a balance of positive 
and negative factors. However, in various disease states, such as tumor progression, 
inflammation, and diabetic retinopathy, deregulated overactive angiogenesis contributes to 
disease progression171.Recent reports suggest that receptor tyrosine kinases (RTKs) of 
endothelial cells play a major role in both physiological and pathological angiogenesis171, 172. 
Two distinct RTK subfamilies are characterized by their abundant expression of 
endothelium. One subfamily consists of VEGF receptors Flt-1/VEGF-R1, Flk-1/VEGF-R2, 
and Flt-4/VEGF-R3173-175. VEGF, also known as vascular permeability factor, is an 
endothelial cell-specific mitogen that induces angiogenesis and increases 
vasopermeability171. 
The other endothelium-specific RTK subfamily is the Tie receptor family, consisting of Tie1 
and Tie2176. Tie1-null mice die in utero with defects that may implicate the hemodynamics of 
transcapillary fluid exchange177, 178. Similarly, Tie2-knockout mice die from day 9.5 to 10.5, 
because of immature vessels and lack of microvessel formation178, 179. Unlike the VEGF 
receptor–knockout mouse180, the number of endothelial cells was normal, and tubular 
formation was detected in Tie2-knockout mice. A mutation in Tie2 in humans was reported to 
cause venous malformations, which are typically an imbalance of endothelial cells and smooth 
muscle cells181. These findings suggest that the Tie2 system has a role in endothelialstromal cell 
communication and in maturation and stabilization of vascular structures. 
Ligands for the Tie2 receptor have been identified as angiopoietin (Ang)-1 and Ang2 182, 183 
and, more recently,Ang3 and Ang4184. Ang1 phosphorylates Tie2 in cultured endothelial 
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cells182, whereas Ang2 does not induce phosphorylation of Tie2, but rather inhibits the 
Ang1-induced phosphorylation of Tie2 in vascular endothelial cells183.Ang2-overexpressing 
transgenic mice die with vascular defects similar to Tie2- or Ang1-knockout mice178, 185. 
These observations suggest that Ang2 acts as a natural antagonist of Tie2 by blocking 
receptor activation by Ang1183. Recently, wide expression of Tie2 in the quiescent 
vasculature of adult tissues was reported186. A study using a corneal angiogenesis model 
revealed that Ang1 and Ang2 facilitates VEGF-induced neovascularization; Ang1 promotes 
vascular network maturation, whereas Ang2 initiates neovascularization187.These data 
support the idea that angiopoietins/Tie2 may have a role not only in embryonic 
angiogenesis, but also in postnatal angiogenesis. 
The renin-angiotensin system (RAS) is known to be a key factor in the cardiovascular 
homeostasis that regulates blood pressure and fluid electrolyte balance188. RAS 
abnormalities have also been reported to play a role in the progression of diabetic 
retinopathy189. Angiotensin II has been reported to regulate cell growth by inducing several 
growth factors190-192. In 1998 and 2000, Atsushi Otani et al reported that Angitensin II 
potentiates VEGF-mediated angiogenic activities through upregulation of VEGF-R2 
expression in bovine retinal endothelial cells (BRECs) and upregulation of VEGF in bovine 
retinal pericytes (BRPs) 193, 194. As RAS played a major role in the retinal angiogenic 
abnormalities associated with diabetes, Atsushi Otani et al investigated the effect of 
angiotensin II (AII) on Ang1 and Ang2 expression in cultured bovine retinal endothelial 
cells(BRECs). Their results showed that AII stimulated Ang2 but not Ang1 mRNA 
expression in a dose- and time-dependent manner. This response was inhibited completely 
by angiotensin type 1 receptor (AT1) antagonist. AII increased the transcription of Ang2 
mRNA, but did not change the half-life. Protein kinase C (PKC) inhibitor completely 
inhibited AIIinduced Ang2 expression, and the mitogen-activated protein kinase (MAPK) 
inhibitor also inhibited it. In addition, the upregulation of Ang2 in an AII-induced in vivo 
rat corneal neovascularization model was also confirmed. These data suggest that AII 
stimulates Ang2 expression through AT1 receptor-mediated PKC and MAPK pathways in 
BREC, and AII may play a novel role in retinal neovascularization195. 
20. Glial cell-derived cytokines 
BRB is a biological unit of retinal vessels with a well-differentiated network, including glial 
cells such as astrocytes and Müller cells, maintaining the retinal microenvironment and low 
permeability. The substantial apparatus of the BRB is a barrier comprised of tight junctions 
between the capillary endothelial cells that strictly regulate the paracellular pathways 
between the cells196. BRB breakdown is closely associated with a number of retinal diseases 
such as diabetic retinopathy, which is characterized by vascular leakage due to increased 
vascular permeability in its early pathogenesis197. 
Hich is believed to be a critical factor in the development of diabetic retinopathy12, 15, 48. 
However, the molecular pharmacology that directly inhibits activated VEGF has not been 
proven to satisfactorily block microangiopathy in diabetic retinopathy198, 199. Glial cell line–
derived neurotrophic factor (GDNF) was originally identified as a neurotrophic 
differentiation factor for dopaminergic neurons in the central nervous system and retina.The 
certain advanced glycation end products could increase the vascular permeability of the 
BRB in vitro by the induction of VEGF and reduction of GDNF expression from glial cells 
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have been demonstrated, suggesting that phenotypic alteration of glial cells in diabetes is 
responsible for the BRB breakdown200-202. 
The vitamin A metabolite all-trans retinoic acid (ATRA) is a potent regulator of cell 
differentiation and an essential signaling molecule in embryonic development and 
throughout life. A study has shown that ATRA can differentiate pluripotent embryonal 
carcinoma cells into neuronal and glial tissues and that it plays an important role in the 
induction of GDNF responsiveness in these cells203. Nami Nishikiori et al demonstrated that 
retinoic acid receptor (RAR)a stimulants preferentially act on glial cells, resulting in the 
enhanced expression of glial cell line–derived neurotrophic factor (GDNF) through 
recruitment of the RARa-driven trans-acting coactivator to the 5´-flanking region of the gene 
promoter. Conversely, RARa decreases expression of VEGF/vascular permeability factor. 
These gene expression alterations causally limit vascular permeability by modulating the 
tight junction function of capillary endothelium in a paracrine manner in vitro. The 
phenotypic transformation of glial cells mediated by RARa is sufficient for significant 
reductions of vascular leakage in the diabetic retina, suggesting that RARa antagonizes the 
loss of tight junction integrity induced by diabetes. These findings reveal that glial cell–
derived cytokines such as GDNF and VEGF regulate BRB function, implying that the glial 
cell can be a possible therapeutic target in diabetic retinopathy204.  
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